
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZC3H14 (Zinc finger CCCH-type containing 14) encodes a poly(A)-binding protein involved in regulation of mRNA metabolism. ZC3H14 influences poly(A) tail length and contributes to control of gene expression by affecting mRNA stability, nuclear export, and translation.
A human hepatocellular carcinoma cell line of Japanese origin, established from the liver tumor of a 57-year-old male patient. The cells are classified as an adult hepatocellular carcinoma line and have been extensively characterized for their molecular and genetic properties. The cell line exhibits a predominantly East Asian genomic ancestry profile and carries documented sequence variations affecting genes including KDR, POLD3, TERT, and TP53.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 6
Reference Transcript: NM_024824
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?